Ethan Russo, M.D., is a board-certified neurologist, psychopharmacology researcher, and Founder/CEO of CReDO Science. He’s one of the leading US-based cannabis scientists.
Prior to his focus on cannabis, Dr. Russo was a clinical neurologist in Missoula, Montana for 20 years. Around 1990, Dr. Russo recognized that his clinical practice patients were being treated with increasingly toxic drugs and often with less and less benefit. With a longstanding keen interest in ethnobotany and medicinal plants, he dove into his initial study of cannabis and migraine headaches. Unfortunately, despite approval of both the FDA and the National Institute on Drug Abuse (NIDA) access to cannabis prevented the study’s completion.
… This is a difference between a medicine and a poison. It has to do with dosing. So we continue to have, for lack of a better term, unjustifiable hysteria about THC.
A subsequently published article on cannabis and migraines by Dr. Russo did capture the attention of the chairman of UK-based GW Pharmaceuticals. Plant material was secured from a Dutch supplier and research was launched which led to the development of the world’s first cannabis plant-based pharmaceutical drugs Sativex and Epidiolex. Epidiolex is CBD based with no THC in its formulation. Sativex contains both THC and CBD in almost a one-to-one ratio.
Dr. Russo joins Dr. Patricia C Frye and Dr. Bonni Goldstein on January 7, 2021 for a live virtual discussion on treating neurologic disorders with medical cannabis and respective research.
